A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma (Q57786339)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Catherine Klersy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Corso A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Zappasodi P

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Mangiacavalli S

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pica G

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Lazzarino M

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

5 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

1545-1548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404682

28 December 2019

exact match

0 references

cites work

Pathogenesis of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Osteoclast inhibition for the treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

7 January 2021

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

7 January 2021

Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

7 January 2021

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404682

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404682

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17410188%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference